Catherine Barrow - Concepedia

Author

Catherine Barrow

Peter MacCallum Cancer Centre

Also Known As

C. Barrow, C. H. Barrow, Catherine Barrow

Publications

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The Netherlands Cancer Institute Merck & Co., Inc., Rahway, NJ, USA (United States)Melanoma Institute Australia The University of Sydney

About

Catherine Barrow is an author at Peter MacCallum Cancer Centre specializing in immunology, medicine, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	538
2	Immunology	4	4	538
3	Surgical Oncology	2	2	434
4	Cancer Therapeutics	2	2	434
5	Allergy	1	1	48

Catherine Barrow

Publications

Citations

H-Index

Page 1

	Year	Citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage Catherine Barrow, Judy Browning, Duncan MacGregor, Clinical Cancer Research	2006	235
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors Jayesh Desai, Hui Gan, Catherine Barrow, Journal of Clinical Oncology	2020	103
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial Matteo S. Carlino, Georgina V. Long, Dirk Schadendorf, European Journal of Cancer	2018	98
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial Andrew Bottomley, Corneel Coens, Justyna Mierzynska, The Lancet Oncology Health-related Quality-of-life ResultsSurgical OncologyOncologyMelanomaImmunology	2021	70
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients Olivier Gasser, Katrina Sharples, Catherine Barrow, Cancer Immunology Immunotherapy VaccinationCancer ImmunosurveillanceHigh-risk Melanoma PatientsPolyfunctional T CellsImmunology	2017	56
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™ Theo Nicholaou, Weisan Chen, Ian D. Davis, Cancer Immunology Immunotherapy VaccinationAllergyVaccine DevelopmentImmunodeficienciesAntigen-specific Immunity	2011	48
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma Alexander M.M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, European Journal of Cancer	2021	27
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma Nathaniel Dasyam, Katrina Sharples, Catherine Barrow, Cancer Immunology Immunotherapy	2023	18

Page 1